Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study

Leuk Lymphoma. 2019 Jun;60(6):1563-1567. doi: 10.1080/10428194.2018.1533130. Epub 2019 Jan 9.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Immunological / therapeutic use*
  • Drug Resistance, Neoplasm
  • Female
  • France / epidemiology
  • Humans
  • Kaplan-Meier Estimate
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology
  • Leukemia, Lymphocytic, Chronic, B-Cell / mortality
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology*
  • Male
  • Multicenter Studies as Topic
  • Recurrence
  • Retreatment
  • Rituximab / therapeutic use*
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Immunological
  • Rituximab